...Luise Grajewski; Christiane Kneifel; Markus Wösle; Ilja F. Ciernik; Lothar Krause Introduction: Local recurrence of conjunctival melanoma (CM) is common after excision. Local radiotherapy is an effective adjuvant treatment option, and brachytherapy with ruthenium-106 ( 106 Ru) is one such option...

... the anatomical and functional outcomes of ruthenium-106 brachytherapy in the management of circumscribed choroidal hemangiomas (CCH). Methods: This is a single-center, retrospective case series including patients with unilateral symptomatic CCH treated with ruthenium-106 brachytherapy at the Cairo University...

... to explore the safety and efficacy of episcleral brachytherapy as a primary management option for eyes with retinal pigment epithelial (RPE) adenoma. Methods: Retrospective chart review of the demographic, clinical, ancillary, and postoperative outcome data of patients with RPE adenoma in 2 tertiary referral...

...Elaine M. Binkley; Sean M. Rodriguez; Daniel E. Hyer; Connie J. Hinz; H. Culver Boldt Introduction: There is an increase in pigmentation that occurs in many tumors following plaque brachytherapy for choroidal melanoma. Correctly distinguishing between increased pigment at the tumor border versus...

...Aya Khasati; Caroline Thaung; Hardeep Singh Mudhar; Bart Wagner; Patricia Goggin; Ian Stoker; Mandeep S. Sagoo; Bertil Damato; Hibba Quhill Introduction: Ruthenium-106 (Ru-106) brachytherapy is one of the commonest eye-sparing treatments for choroidal melanoma. These patients require long-term...

...Aaron A. Gurayah; Vanessa A. Peters; William Jin; Karthik Kalahasty; Deukwoo Kwon; Wei Zhao; Nirav V. Patel; Arnold M. Markoe; Zelia M. Correa; Matthew T. Studenski; J. William Harbour; Stuart E. Samuels Introduction: Iodine-125 brachytherapy is an effective eye-sparing treatment for uveal melanoma...

...-106 Brachytherapy The treatment of juxtapapillary choroidal melanomas is challenging as any treatment involves radiation to visually crucial structures – the optic nerve and macula. These tumours are also known to have high recurrence rates (0–50%) [1-3]. Various eye-conserving radiation...

... brachytherapy with 125-I seeds; analyse cause-specific survival (CSS), metastasis-free survival (MFS), and local control; and establish the relationship between tumour size and metastases. Methods: From May 2007 to February 2013, 88 patients classified according to the American Joint Committee on Cancer...

...(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Brachytherapy Conjunctival melanoma Ocular oncology Ocular tumors Ophthalmic oncology Conjunctival malignant...

... with ruthenium-106 (Ru-106) plaque types CCB and CCC using UBM. Methods: This single institution-based retrospective case series involved 10 Caucasian patients with AUM followed after brachytherapy with UBM from January 2014 until February 2019. The largest prominence of the tumor perpendicular to the sclera...

...Peter S. Fagerberg; Ingvild M.S. Ramberg; Peter B. Toft Background: Separately, cryotherapy and brachytherapy have shown promising results when adjuvating the excision of squamous cell carcinoma of the conjunctiva (SCCC). The aim of this paper is to assess the combined effect in terms...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Monte Carlo Brachytherapy PENELOPE Ruthenium Eye plaques β-Emitter Treatment planning...

... patterns for I-125 plaque brachytherapy in the United States by studying practice patterns at centers that comprise the Ocular Oncology Study Consortium (OOSC). Methods: The OOSC database and responses to a treatment practice survey were evaluated. The database contains treatment information from 9...

...Jesintha Navaratnam; Thomas P. Bærland; Nils A. Eide; Rowan T. Faber; Bernt L. Rekstad; Demetrios G. Vavvas; Ragnheiður Bragadóttir Background: Early confirmation of the effect of brachytherapy for choroidal melanoma showing that tumour coverage is valuable. The irradiated retinal pigment...

...Gustav Stålhammar; Thonnie Rose See; Maria Filì; Stefan Seregard Background: In several malignancies, gender-based survival differences after specific therapeutic interventions have been demonstrated. It is not known whether such differences exist after plaque brachytherapy of uveal melanoma...

...Benjamin A. King; Caroline Awh; Brad T. Gao; Jiajing Wang; Mehmet Kocak; Vanessa M. Morales-Tirado; Matthew T. Ballo; Matthew W. Wilson Background/Aims: The aim of this study is to report the burden of ocular morbidity following iodine-125 episcleral plaque brachytherapy (EPBT) in the treatment...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Monte Carlo simulation Brachytherapy PENELOPE Ruthenium Eye plaques...

...Wu Liu; Jenna May Kim; Benjamin K. Young; Ravinder Nath; Zhe Chen; Roy H. Decker; Melvin A. Astrahan; Renelle Pointdujour-Lim Background: While traditional eye plaque brachytherapy can be used for the treatment of iris melanoma, it faces challenges of poor patient tolerability due to cornea-plaque...

...%, ciliochoroidal in 9%, iridociliary in 2%, and iris in 7%. Treatment modalities included brachytherapy (ruthenium-106 and iodine-125 [64%]), enucleation (27%), and proton beam radiation (8%). The mean age-adjusted incidence of uveal melanoma in Ireland from 2010 to 2015 was 9.5 per million of the population (95...

... treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up. Orbital exenteration has not demonstrated significant improvement...